Golimumab (anti-TNF monoclonal antibody): where we stand today
AT Melo, R Campanilho-Marques… - Human Vaccines & …, 2021 - Taylor & Francis
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been
implicated in the pathophysiology of several chronic immune-mediated inflammatory …
implicated in the pathophysiology of several chronic immune-mediated inflammatory …
Effectiveness of golimumab in ulcerative colitis: a review of the real world evidence
Background Biologics against tumor necrosis factor (anti-TNF) have dramatically changed
the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials …
the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials …
[HTML][HTML] Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study
L Bertani, C Blandizzi, MG Mumolo… - Clinical and …, 2020 - journals.lww.com
METHODS: A prospective observational study was conducted on patients with ulcerative
colitis, who started biological therapy with infliximab, adalimumab, golimumab, or …
colitis, who started biological therapy with infliximab, adalimumab, golimumab, or …
Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis: a post hoc analysis of GEMINI 1
W Reinisch, B Bressler, R Curtis… - Inflammatory bowel …, 2019 - academic.oup.com
Background In patients with ulcerative colitis (UC), fecal calprotectin (FC) concentrations
correlate with endoscopic inflammation evidence. This study investigated the effect of …
correlate with endoscopic inflammation evidence. This study investigated the effect of …
[PDF][PDF] Effectiveness and factors associated with response to golimumab in Japanese patients with ulcerative colitis in real clinical practice: the phoenix study
D Hirayama, S Motoya, T Ashida, K Ando… - Inflammatory Intestinal …, 2023 - karger.com
Introduction: There have been limited reports on the clinical efficacy of golimumab (GLM) in
Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to …
Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to …
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: a multicenter, observational study in primary inflammatory bowel …
A Tursi, G Mocci, R Faggiani, L Allegretta… - European journal of …, 2019 - Elsevier
Background Italian data currently available in managing ulcerative colitis (UC) and Crohn's
disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary …
disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary …
Early mucosal healing predicts favorable outcomes in patients with moderate to severe ulcerative colitis treated with golimumab: data from the real-life BE-SMART …
P Bossuyt, F Baert, F D'Heygere… - Inflammatory bowel …, 2019 - academic.oup.com
Background Golimumab (GOL) is registered for moderate to severely active ulcerative colitis
(UC). Data on the use of GOL in daily clinical practice are limited. Currently, it is unclear …
(UC). Data on the use of GOL in daily clinical practice are limited. Currently, it is unclear …
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers
A Tursi, W Elisei, R Faggiani, L Allegretta… - Medicine, 2018 - journals.lww.com
Adalimumab (ADA) was approved in Italy for the treatment of ulcerative colitis (UC)
unresponsive to standard treatments in 2014, but no data from real life are currently …
unresponsive to standard treatments in 2014, but no data from real life are currently …
Pharmacotherapy of ulcerative colitis–current status and emerging trends
H Ahmad, VL Kumar - Journal of basic and clinical physiology and …, 2018 - degruyter.com
Ulcerative colitis (UC) is a chronic mucosal inflammation of the large intestine restricted to
the rectum and colon. Its clinical course follows an intermittent pattern with episodes of …
the rectum and colon. Its clinical course follows an intermittent pattern with episodes of …
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG
C Eriksson, I Visuri, L Vigren, L Nilsson… - Scandinavian Journal …, 2021 - Taylor & Francis
Objectives Clinical trials demonstrated that golimumab is effective in anti-TNF naïve patients
with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real …
with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real …